India has spent two decades earning the nickname "pharmacy of the world" for churning out affordable generic medicines. Now the government says that isn't enough.
Union Minister Anupriya Patel argued that India must use artificial intelligence and pharmaceutical research to move beyond manufacturing and become a global hub for drug discovery and healthcare, according to a Moneycontrol report. Patel framed the shift with a phrase worth noting: India should aim to be the "laboratory of the world," and AI should also help bridge gaps in healthcare access.
The distinction matters more than it might sound. Making a generic drug means copying a molecule someone else discovered — valuable work, but low-margin and downstream. Discovering the molecule in the first place is where the money, the patents, and the scientific prestige live. AI has become the fashionable shortcut in that race, with drug companies worldwide betting that machine learning can compress the years spent screening chemical candidates.
A parallel piece of the story is the plumbing. In an industry commentary published by NewsX, Diana Tran, Principal Product Marketing Manager at Revvity Signals, writes about how integrated scientific workflows are redefining strategic advantage for India's pharmaceutical and biotechnology sectors. The unglamorous point behind that phrase: AI is only as good as the lab data feeding it, and research organizations that connect their instruments, experiments, and records into one usable stream get more out of the technology than those with data scattered across silos.
Neither source details funding figures, timelines, or specific programs, so the ambition currently sits at the level of stated intent rather than announced policy.
Why it matters: if India succeeds in moving from copying drugs to inventing them, it changes both who profits from the next generation of medicines and how quickly affordable versions reach the patients who need them.